HSS Medical Supply to Distribute Abbott’s Rapid Molecular Testing Platform
The agreement adds Abbott's ID NOW system to the distributor's portfolio, offering rapid point-of-care testing for respiratory infections and Strep A.
The agreement adds Abbott's ID NOW system to the distributor's portfolio, offering rapid point-of-care testing for respiratory infections and Strep A.
Abbott has launched a next-generation Oncodetect MRD test that uses whole-genome sequencing to track up to 5,000 patient-specific cancer variants, offering a 30-fold increase in detection sensitivity, according to the company.
Quest Diagnostics and Waters Corp will expand at-home HPV screening nationwide in 2027, offering extended genotyping via the FDA-cleared Onclarity Self-Collection Kit through clinical, health plan, and consumer channels.
UNC and Tulane researchers have developed a CRISPR-based microfluidic assay that identifies 15 nontuberculous mycobacteria species directly from clinical specimens in 3.5 hours, with over 97% sensitivity, according to a recent study.
Read MoreA multicenter study led by Children’s Hospital Colorado finds that skin biopsy fibroblast assays can help diagnose primary mitochondrial diseases, potentially reducing the need for invasive muscle and liver biopsies.
Read MoreCastle Biosciences’ new data presented at ACG 2026 show the TissueCypher test offers objective risk stratification for Barrett’s esophagus progression, providing information beyond standard histopathology.
Read MoreAs molecular diagnostics expand what laboratories can detect, laboratories are placing greater emphasis on matching the breadth of testing to the patient and how the results will be used.
Read MoreAn independent validation study of 426 patients evaluated the assay’s ability to assess 10-year recurrence risk and identify patients more likely to benefit from radiation therapy.
Read MoreDiagnostic lab, molecular, and genomics claim denials rose 40% to 11.2% in 2025, driven by insurer automation and more prior authorization rejections, according to XiFin’s 2026 Payor Denial Impact Report.
Read MoreA new federal directive tasks HHS with launching rapid diagnostic R&D for vector-borne diseases, emphasizing decentralized molecular testing as part of a broader strategy to improve local pathogen surveillance.
Read More10x Genomics and Fred Hutchinson Cancer Center have launched a multi-project collaboration to study single cell and spatial profiling for cancer diagnostics, including biomarkers in bladder cancer and residual disease detection in AML.
Read MoreCerenome has launched two CSF-based molecular profiling tests for CNS cancers, offering DNA and RNA sequencing panels to evaluate primary, metastatic, and hematologic malignancies in the central nervous system.
Read MorePillar Biosciences has introduced the oncoReveal Myeloid v2 Panel, expanding its NGS assay from 58 to 80 genes and enhancing FLT3-ITD detection while maintaining existing laboratory workflows.
Read MoreCastle Biosciences’ TissueCypher test informed management changes in 90% of non-dysplastic Barrett’s esophagus cases in a 30-patient study at Keck Medical Center, according to results published in Foregut.
Read MoreA study found that Quest Diagnostics’ Haystack MRD ctDNA test detected colorectal cancer recurrence with up to 100% specificity, outperforming CEA testing in DYNAMIC trial patient specimens.
Read MoreA Stanford-led study found that Resero Bio’s uRARE-seq urine cfRNA test can non-invasively detect bladder cancer, assess tumor grade, and predict therapy response in 683 patient samples.
Read MoreRenew Biotechnologies and Mayo Clinic have partnered to evaluate NeuroLens, a cfDNA-based test, for monitoring central nervous system injury and disease progression in multiple sclerosis and related neuroimmunologic conditions.
Read MoreRoche subsidiary TIB MOLBIOL has launched a CE-marked newborn screening kit that simultaneously tests for spinal muscular atrophy, severe combined immunodeficiency, and sickle cell disease in laboratories across Europe.
Read More